Earnings History Data for Fresh Tracks Therapeutics, Inc. (FRTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics Inc. is a clinical-stage pharmaceutical company. Its product pipeline includes Cialis(R), Taltz(R), Gemzar(R), Prozac(R), Cymbalta(R), Juvederm(R), Pluvicto(R) and Sofpironium Bromide. Fresh Tracks Therapeutics Inc., formerly known as Brickell Biotech Inc., is based in BOULDER, Colo.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-05-2023	AH		FRTX	Fresh Tracks Therapeutics, Inc.	2.91	-1.14	0.00	-3.60	Fresh Tracks Therapeutics GAAP EPS of -$1.14 [5/10/2023 5:13 PM]	0.5336	0.02 (3.31%)	0.0	0.0 (0.00%)	0.45 - 12.60	75,426	80,000	0
Fresh Tracks Therapeutics GAAP EPS of -$1.14 [5/10/2023 5:13 PM]
10-11-2022	AH	After the close (Nov 10)	FRTX	Fresh Track Therapeutics, Inc.	4.97	-2.07	-1.89	-7.21	Fresh Tracks Therapeutics reports GAAP EPS of -$2.07, revenue of $0.49M [11/10/2022 4:23 PM]	1.88	0.11 (6.21%)	1.74	-0.03 (-1.69%)	1.67 - 18.94	40,904	30,000	177
Fresh Tracks Therapeutics reports GAAP EPS of -$2.07, revenue of $0.49M [11/10/2022 4:23 PM] Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-10-22 04:05PM]